美国临床肿瘤学会多基因检测临床实践指南更新及临床意义

Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer

近年来,随着多基因检测在早期浸润性乳腺癌患者辅助化疗决策中的使用,早期浸润性乳腺癌的综合诊治理念已在细化解剖学分期,精确掌握宏观肿瘤负荷的基础上,跨越到结合基因检测信息、分析肿瘤生物学特性,实施个体化治疗以达到损伤最小化的新阶段。2017年7月《临床肿瘤学杂志》(Journal of Clinical Oncology,JCO)刊登美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)多基因检测临床指南更新内容,其中,针对不同人群多基因检测提出推荐意见,重点提高了MammaPrint~临床应用的推荐强度,旨在科学指导临床医生合理地制定治疗决策,避免过度医疗。

In recent years, multigene tests have been recommended to guide decisions on the need of adjuvant chemotherapy for patients with early-stage breast cancer. The comprehensive strategy of early-stage breast cancer has come into an era, when both anatomic tumor burden and multigene test results should be taken into consideration to gain a better understanding of tumor biology and personalized treatment, in order to minimize toxic effects. In July 2017, the Journal of Clinical Oncology （JCO） published the new version of the clinical practice guideline of American Society of Clinical Oucology （ASCO） on the use of biomarkers to guide therapeutic decision for breast cancer. The guideline provided criteria of clinical utility for different patient groups, and focused on the recommendation of MammaPrint with evidence of high quality, leading to reasonable decision-making for clinicians to avoid overtreatment.